[go: up one dir, main page]

MX2019010169A - Compuestos novedosos utiles como abridores del canal de potasio. - Google Patents

Compuestos novedosos utiles como abridores del canal de potasio.

Info

Publication number
MX2019010169A
MX2019010169A MX2019010169A MX2019010169A MX2019010169A MX 2019010169 A MX2019010169 A MX 2019010169A MX 2019010169 A MX2019010169 A MX 2019010169A MX 2019010169 A MX2019010169 A MX 2019010169A MX 2019010169 A MX2019010169 A MX 2019010169A
Authority
MX
Mexico
Prior art keywords
groups
substituted
unsubstituted
potassium channel
novel compounds
Prior art date
Application number
MX2019010169A
Other languages
English (en)
Other versions
MX378574B (es
Inventor
Bös Michael
Original Assignee
Acousia Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acousia Therapeutics Gmbh filed Critical Acousia Therapeutics Gmbh
Publication of MX2019010169A publication Critical patent/MX2019010169A/es
Publication of MX378574B publication Critical patent/MX378574B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/78Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/28Halogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/26Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of rings other than six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/40Y being a hydrogen or a carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/43Y being a hetero atom
    • C07C323/44X or Y being nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/63Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cosmetics (AREA)
  • Fertilizers (AREA)

Abstract

La descripción actual describe compuestos novedosos que son útiles como abridores del canal de potasio, en particular como abridores del canal de potasio Kv7.4. Los compuestos novedosos son compuestos de acuerdo con la fórmula I, (ver fórmula) en donde - n = 0 o 1, - RL es un sustituyente seleccionado del grupo que consiste de grupos cicloalquilo sustituidos o no sustituidos, en particular grupos bicicloalquilo, grupos fenilo sustituidos o no sustituidos, grupos tienilo sustituidos o no sustituidos o grupos ciclopentatienilo, y grupos indanilo sustituidos o no sustituidos, que opcionalmente contienen heteroátomos, y - RR es un sustituyente seleccionado del grupo que consiste de grupos fenilo sustituidos o no sustituidos o grupos bencilo sustituidos o no sustituidos, que opcionalmente contienen heteroátomos, - o un estereoisómero, un tautómero, un profármaco o una sal, preferiblemente sal farmacéuticamente aceptable del mismo.
MX2019010169A 2017-02-28 2018-02-27 Compuestos novedosos utiles como abridores del canal de potasio MX378574B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17158326.3A EP3366683A1 (en) 2017-02-28 2017-02-28 Cyclic amides, acteamides and ureas useful as potassium channel openers
PCT/EP2018/054820 WO2018158256A2 (en) 2017-02-28 2018-02-27 Novel compounds useful as potassium channel openers

Publications (2)

Publication Number Publication Date
MX2019010169A true MX2019010169A (es) 2019-10-21
MX378574B MX378574B (es) 2025-03-10

Family

ID=58192162

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020010866A MX390303B (es) 2017-02-28 2018-02-27 Compuestos novedosos utiles como abridores del canal de potasio
MX2019010169A MX378574B (es) 2017-02-28 2018-02-27 Compuestos novedosos utiles como abridores del canal de potasio

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020010866A MX390303B (es) 2017-02-28 2018-02-27 Compuestos novedosos utiles como abridores del canal de potasio

Country Status (25)

Country Link
US (2) US11034665B2 (es)
EP (3) EP3366683A1 (es)
JP (3) JP6795713B2 (es)
KR (2) KR102443685B1 (es)
CN (2) CN110312710B (es)
AU (2) AU2018227005B2 (es)
BR (2) BR112019017184B1 (es)
CA (2) CA3052359C (es)
CL (2) CL2019002445A1 (es)
CY (2) CY1123114T1 (es)
DK (2) DK3567034T3 (es)
ES (2) ES2813064T3 (es)
HR (2) HRP20201159T1 (es)
HU (2) HUE051854T2 (es)
IL (1) IL268931B (es)
LT (2) LT3567034T (es)
MX (2) MX390303B (es)
PH (1) PH12019550146A1 (es)
PL (2) PL3567034T3 (es)
PT (2) PT3484863T (es)
RS (2) RS61254B1 (es)
SI (2) SI3567034T1 (es)
SM (2) SMT202000471T1 (es)
WO (1) WO2018158256A2 (es)
ZA (1) ZA201905198B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3366683A1 (en) * 2017-02-28 2018-08-29 Acousia Therapeutics GmbH Cyclic amides, acteamides and ureas useful as potassium channel openers
EP4414029A3 (en) 2019-09-17 2024-11-06 Knopp Biosciences LLC Methods of use for kv7 channel activators
EP4143165A1 (en) 2020-04-29 2023-03-08 Idorsia Pharmaceuticals Ltd Spirourea derivatives
EP4172140A1 (en) 2020-06-25 2023-05-03 Idorsia Pharmaceuticals Ltd Cyclobutyl-urea derivatives
CA3198930A1 (en) * 2020-11-19 2022-05-27 Acousia Therapeutics Gmbh Non-aqueous gel composition
CN116535353A (zh) * 2022-01-25 2023-08-04 上海挚盟医药科技有限公司 作为钾通道调节剂的酰胺类化合物及其制备和应用
EP4279061A1 (en) * 2022-05-18 2023-11-22 Acousia Therapeutics GmbH Aqueous gel composition

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0594034A (ja) 1990-06-29 1993-04-16 Xerox Corp クラツクのない電子写真画像形成デバイス
DK0957099T3 (da) * 1998-04-15 2003-03-17 Pfizer Prod Inc Heterocykliske carboxamider
DE19929076A1 (de) * 1999-06-25 2000-12-28 Aventis Pharma Gmbh Indanylsubstituierte Benzolcarbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10061876A1 (de) * 2000-12-12 2002-06-20 Aventis Pharma Gmbh Arylierte Furan- und Thiophencarbonsäureamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
WO2002080898A2 (en) 2001-04-04 2002-10-17 Wyeth Methods for treating hyperactive gastric motility
US7273866B2 (en) * 2002-12-20 2007-09-25 Bristol-Myers Squibb Company 2-aryl thiazole derivatives as KCNQ modulators
MXPA05010000A (es) 2003-03-21 2005-11-17 Lundbeck & Co As H Derivados de p-diaminobenceno substituidos.
TWI357901B (en) 2004-03-12 2012-02-11 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivati
UA89503C2 (uk) 2004-09-13 2010-02-10 Х. Луннбек А/С Заміщені похідні аніліну
US20060188445A1 (en) 2005-02-22 2006-08-24 Fred Hutchinson Cancer Research Center Assay for compounds that protect against sensory hair cell death and compounds identified by same
US7790770B2 (en) * 2005-11-23 2010-09-07 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
WO2007087424A2 (en) 2006-01-25 2007-08-02 The Johns Hopkins University Method of treating kcnq related disorders using organozinc compounds
WO2007138112A2 (en) 2006-06-01 2007-12-06 Devgen N.V. Compounds that interact with ion channels, in particular with ion channels from the kv family
US20090118274A1 (en) 2007-02-15 2009-05-07 Darin Allen Monocyclic aminopropyl tetrahydro-pyrazolo-pyridine modulators of cathepsin s
DE102007063673B4 (de) 2007-07-10 2018-02-08 Heraeus Electro-Nite International N.V. Messverfahren
UA97847C2 (ru) * 2007-08-01 2012-03-26 Х. Луннбек А/С Применение соединений, которые открывают калиевые каналы kcnq, для лечения дефицита внимания/гиперактивности (adhd) или агрессии
WO2009052062A1 (en) 2007-10-17 2009-04-23 Sanofi-Aventis Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
CN101896461A (zh) * 2007-12-13 2010-11-24 安姆根有限公司 γ分泌酶调节剂
US7786171B2 (en) * 2008-04-04 2010-08-31 Abbott Laboratories Amide derivatives as positive allosteric modulators and methods of use thereof
TW201038572A (en) 2009-03-25 2010-11-01 Gruenenthal Gmbh Substituted spiro-amide compounds
US20120220577A1 (en) * 2009-06-04 2012-08-30 Merz Pharma Gmbh & Co Kgaa Glycine b antagonists
WO2011085351A2 (en) 2010-01-11 2011-07-14 The Johns Hopkins University Method of treating kcnq related disorders
DE102010007281A1 (de) 2010-02-08 2011-08-11 EMC microcollections GmbH, 72070 Neue Aminoalkyl-oxazol- und Aminoalkyl-thiazolcarbonsäureamide und ihre Anwendung zur Stimulation der endogenen situ Regeneration von Haarsinneszellen im Corti'schen Organ des Innenohres beim Säuger
US8586604B2 (en) * 2010-08-20 2013-11-19 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin E2 synthase-1
TW201217312A (en) 2010-09-22 2012-05-01 Gruenenthal Gmbh Substituted benzamide compounds
EP3321257A1 (en) * 2012-02-23 2018-05-16 Vanderbilt University Substituted 5-aminothieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
AU2013323206B2 (en) 2012-09-28 2017-07-20 Fred Hutchinson Cancer Center Compounds and methods for preventing, treating and/or protecting against sensory hair cell death
WO2014079850A1 (en) * 2012-11-23 2014-05-30 F. Hoffmann-La Roche Ag Substituted heterocyclic derivatives
WO2014145205A2 (en) * 2013-03-15 2014-09-18 St. Jude Children's Research Hospital Methods and compositions of p27kip1 transcription modulators
PL404138A1 (pl) * 2013-05-31 2014-12-08 Warszawski Uniwersytet Medyczny Pochodne kwasu benzoesowego jako inhibitory receptora IL-15Rα
US20150126507A1 (en) * 2013-09-05 2015-05-07 Fate Therapeutics, Inc. Compounds to treat hearing loss
JP6378774B2 (ja) * 2013-11-05 2018-08-22 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 自己免疫疾患を処置するためのRORcモジュレーターとしての5,6,7,8−テトラヒドロ−5,8−メタノシンノリン誘導体
ES2607752T3 (es) * 2013-11-12 2017-04-03 Acousia Therapeutics Gmbh Compuestos nuevos para regeneración de células y tejidos terminalmente diferenciados
CN105017085B (zh) 2014-04-28 2018-06-29 中国科学院上海药物研究所 一类kcnq钾通道激动剂、其制备方法和用途
US10399994B2 (en) * 2015-02-06 2019-09-03 University Of Washington Compounds and methods for preventing or treating sensory hair cell death
GB201601301D0 (en) 2016-01-25 2016-03-09 Takeda Pharmaceutical Novel compounds
EP3366683A1 (en) 2017-02-28 2018-08-29 Acousia Therapeutics GmbH Cyclic amides, acteamides and ureas useful as potassium channel openers

Also Published As

Publication number Publication date
MX2020010866A (es) 2022-02-28
PL3567034T3 (pl) 2021-05-17
CY1123114T1 (el) 2021-10-29
BR112019017184A2 (pt) 2020-04-28
KR20190105058A (ko) 2019-09-11
KR20210134826A (ko) 2021-11-10
MX378574B (es) 2025-03-10
EP3484863B1 (en) 2020-06-17
MX390303B (es) 2025-03-20
ES2813064T3 (es) 2021-03-22
HRP20201961T1 (hr) 2021-02-05
CN114105942B (zh) 2024-07-12
CN110312710B (zh) 2022-02-15
PT3567034T (pt) 2020-12-04
KR102382795B1 (ko) 2022-04-05
HUE052703T2 (hu) 2021-05-28
AU2018227005B2 (en) 2021-11-11
HUE051854T2 (hu) 2021-03-29
EP3567034A1 (en) 2019-11-13
IL268931A (en) 2019-10-31
BR122020025103B1 (pt) 2021-06-01
JP7474289B2 (ja) 2024-04-24
WO2018158256A3 (en) 2018-12-13
PH12019550146A1 (en) 2020-06-08
US11884642B2 (en) 2024-01-30
RS61254B1 (sr) 2021-01-29
RS60648B1 (sr) 2020-09-30
RU2020140167A (ru) 2020-12-16
SMT202100053T1 (it) 2021-03-15
LT3484863T (lt) 2020-07-27
CY1123488T1 (el) 2022-03-24
ZA201905198B (en) 2020-03-25
PT3484863T (pt) 2020-08-27
US20200157072A1 (en) 2020-05-21
CA3238405A1 (en) 2018-09-07
JP2022166055A (ja) 2022-11-01
JP2020510694A (ja) 2020-04-09
IL268931B (en) 2021-10-31
CN114105942A (zh) 2022-03-01
US11034665B2 (en) 2021-06-15
SI3484863T1 (sl) 2020-10-30
AU2021254653A1 (en) 2021-11-18
AU2021254653B2 (en) 2022-12-08
WO2018158256A2 (en) 2018-09-07
CL2019002445A1 (es) 2020-03-13
ES2846772T3 (es) 2021-07-29
CA3052359A1 (en) 2018-09-07
AU2018227005A1 (en) 2019-08-22
RU2019127116A3 (es) 2021-03-31
RU2020140167A3 (es) 2021-04-23
EP3484863A2 (en) 2019-05-22
SI3567034T1 (sl) 2021-03-31
CL2021001243A1 (es) 2021-10-22
SMT202000471T1 (it) 2020-11-10
US20210261518A1 (en) 2021-08-26
CA3052359C (en) 2025-10-21
DK3567034T3 (da) 2021-01-11
JP2021008479A (ja) 2021-01-28
RU2019127116A (ru) 2021-03-30
HRP20201159T1 (hr) 2020-11-13
LT3567034T (lt) 2020-12-10
PL3484863T3 (pl) 2020-12-14
KR102443685B1 (ko) 2022-09-15
EP3366683A1 (en) 2018-08-29
BR112019017184B1 (pt) 2021-06-01
CN110312710A (zh) 2019-10-08
EP3567034B1 (en) 2020-10-28
JP6795713B2 (ja) 2020-12-02
DK3484863T3 (da) 2020-09-07

Similar Documents

Publication Publication Date Title
MX2019010169A (es) Compuestos novedosos utiles como abridores del canal de potasio.
CL2020001547A1 (es) Carbamoíl ciclohexil ácidos ligados a n de triazol como antagonistas de lpa.
UY37854A (es) Derivados de 3- (1-oxoisoindolin-2-il) piperidina-2,6-diona y usos de los mismos
AR122783A2 (es) Inhibidores de kras g12c y métodos para su uso
AR108711A1 (es) Compuestos moduladores de fxr (nr1h4)
CO2019009423A2 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos
ECSP17082683A (es) Compuestos antifúngicos
CU20190086A7 (es) Compuestos de heteroarilo bicíclicos 6-6 fusionados útiles como inhibidores de lats
MX375323B (es) Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos.
CO2017003838A2 (es) Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos
CL2022000802A1 (es) Compuestos heterocíclicos de arilmetileno como bloqueadores del canal shaker de potasio kv1.3
CO6531444A2 (es) Métodos sintéticos para compuestos espiro-oxoindol
MX2018007774A (es) Compuestos heterociclicos como inmunomoduladores.
UY36462A (es) Compuestos de triazolopirimidina y usos de los mismos
EA201992322A2 (ru) Соединения и композиции для лечения гематологических расстройств
EA201592126A1 (ru) 6-мостиковые гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
ECSP18024565A (es) Benzamidas sustituidas con isoxazolinas y análalogos como insecticidas
MX2022004168A (es) Compuestos aromaticos de arilmetileno a manera de bloqueadores del canal de potasio kv1.3.
UY36257A (es) “compuestos de imidazopiridazina”.
AR104731A1 (es) Benzamidas sustituidas y métodos para utilizarlas
UY37774A (es) Compuestos 5-cianoindol sustituidos y usos de los mismos
MX2019003545A (es) Compuestos heterociclicos y uso de los mismos para prevenir o tratar infecciones bacterianas.
AR109328A1 (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
MX2018010177A (es) Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxa mida.
UY37641A (es) Compuestos de isoxazol carboxamida y usos de los mismos